Kevin L Peterson
Overview
Explore the profile of Kevin L Peterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Venkatachalam A, Correia C, Peterson K, Hou X, Schneider P, Strathman A, et al.
Mol Cancer
. 2024 Oct;
23(1):224.
PMID: 39375715
Recent studies indicate that replication checkpoint modulators (RCMs) such as inhibitors of CHK1, ATR, and WEE1 have promising monotherapy activity in solid tumors, including platinum-resistant high grade serous ovarian cancer...
2.
Guru Murthy G, Saliba A, Szabo A, Harrington A, Abedin S, Carlson K, et al.
Haematologica
. 2024 Apr;
109(9):2864-2872.
PMID: 38572562
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed acute myeloid leukemia (AML). However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of...
3.
Jia J, Ji W, Saliba A, Csizmar C, Ye K, Hu L, et al.
Cell Death Differ
. 2024 Mar;
31(4):405-416.
PMID: 38538744
BH3 mimetics, including the BCL2/BCLX/BCLw inhibitor navitoclax and MCL1 inhibitors S64315 and tapotoclax, have undergone clinical testing for a variety of neoplasms. Because of toxicities, including thrombocytopenia after BCLX inhibition...
4.
Jayaraman S, Wu X, Kalari K, Tang X, Kuffel M, Bruinsma E, et al.
NPJ Breast Cancer
. 2023 Dec;
9(1):101.
PMID: 38114522
Endoxifen, a secondary tamoxifen metabolite, is a potent antiestrogen exhibiting estrogen receptor alpha (ERα) binding at nanomolar concentrations. Phase I/II clinical trials identified clinical activity of Z-endoxifen (ENDX), in endocrine-refractory...
5.
Al-Kali A, Aldoss I, Atherton P, Strand C, Shah B, Webster J, et al.
Cancer Med
. 2023 Nov;
12(23):21229-21239.
PMID: 37960985
Background: Despite recent approval of several new agents, relapsed acute lymphoblastic leukemia (ALL) remains challenging to treat. Sapanisertib (MLN0128/TAK-228) is an oral TORC1/2 inhibitor that exhibited preclinical activity against ALL....
6.
Dai H, Peterson K, Flatten K, Meng X, Venkatachalam A, Correia C, et al.
Cell Death Differ
. 2022 Nov;
30(3):794-808.
PMID: 36376382
How BAK and BAX induce mitochondrial outer membrane (MOM) permeabilization (MOMP) during apoptosis is incompletely understood. Here we have used molecular dynamics simulations, surface plasmon resonance, and assays for membrane...
7.
Saliba A, Kaufmann S, Stein E, Patel P, Baer M, Stock W, et al.
Blood Adv
. 2022 Oct;
7(11):2360-2363.
PMID: 36315007
No abstract available.
8.
Meng X, Peterson K, Dai H, Schneider P, Lee S, Zhang J, et al.
J Biol Chem
. 2022 May;
298(5):101980.
PMID: 35490622
No abstract available.
9.
Wahner Hendrickson A, Visscher D, Hou X, Goergen K, Atkinson H, Beito T, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885153
The poly(ADP-ribose) binding protein CHFR regulates cellular responses to mitotic stress. The deubiquitinase UBC13, which regulates CHFR levels, has been associated with better overall survival in paclitaxel-treated ovarian cancer. Despite...
10.
Hurley R, McGehee C, Nesic K, Correia C, Weiskittel T, Kelly R, et al.
NAR Cancer
. 2021 Jul;
3(3):zcab028.
PMID: 34316715
Acquired PARP inhibitor (PARPi) resistance in - or -mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. is a less commonly studied ovarian cancer susceptibility...